Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:advocates_for |
engaged with patient advocacy groups
|
| gptkbp:brand |
attempted to rebrand company
|
| gptkbp:business_model |
biopharmaceuticals
|
| gptkbp:ceo |
gptkb:John_H._Johnson
|
| gptkbp:clinical_trial |
gptkb:vaccine
Phase III trial for Provenge metastatic castrate-resistant prostate cancer reported positive clinical trial results |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:committee |
composed of experts
|
| gptkbp:competitors |
other cancer immunotherapy companies
|
| gptkbp:conflict |
experienced financial difficulties
faced significant business challenges |
| gptkbp:financial_products |
gptkb:2014
|
| gptkbp:focus |
cancer immunotherapy
|
| gptkbp:founded |
gptkb:1992
|
| gptkbp:founder |
Mitchell H. Gold
|
| gptkbp:future_plans |
uncertain future outlook.
|
| gptkbp:headcount |
approximately 500 employees
|
| gptkbp:headquarters |
gptkb:Seattle,_Washington
|
| gptkbp:healthcare |
April 2010
collaborated with healthcare providers expanded patient access programs |
| https://www.w3.org/2000/01/rdf-schema#label |
Dendreon
|
| gptkbp:industry |
gptkb:Company
|
| gptkbp:invention |
multiple patents on technology
|
| gptkbp:investment |
various venture capital firms
volatile stock performance |
| gptkbp:is_effective_against |
improved survival rates
|
| gptkbp:language_of_instruction |
developing additional therapies
|
| gptkbp:market |
gptkb:United_States
withdrew from certain markets |
| gptkbp:marketing_strategy |
direct-to-physician marketing
|
| gptkbp:partnership |
gptkb:Astellas_Pharma
|
| gptkbp:partnerships |
formed strategic partnerships
|
| gptkbp:population |
men with prostate cancer
|
| gptkbp:production_location |
gptkb:New_Jersey
|
| gptkbp:products |
therapeutic vaccine
Provenge |
| gptkbp:provides_information_on |
included in treatment guidelines
|
| gptkbp:publishes |
published research findings
|
| gptkbp:receives_funding_from |
secured funding from investors
|
| gptkbp:regulatory_compliance |
faced several regulatory hurdles
|
| gptkbp:research_areas |
oncology
|
| gptkbp:research_focus |
personalized medicine
|
| gptkbp:revenue |
$100 million (2011)
|
| gptkbp:symbol |
DNDN
|
| gptkbp:targets |
gptkb:healthcare_organization
|
| gptkbp:technology |
dendritic cell therapy
|
| gptkbp:treatment |
monitored for effectiveness
|